We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Spire Healthcare Group Plc | LSE:SPI | London | Ordinary Share | GB00BNLPYF73 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 185.00 | 609,290 | 16:35:09 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 185.60 | 186.00 | 187.60 | 184.80 | 187.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Health & Allied Services,nec | 1.51B | 25.4M | 0.0631 | 29.38 | 745.09M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:42:14 | O | 75,343 | 185.1666 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/4/2025 | 15:20 | UK RNS | Spire Healthcare Group PLC Director/PDMR Shareholding |
| 08/4/2025 | 12:30 | UK RNS | Spire Healthcare Group PLC Annual Financial Report |
| 01/4/2025 | 10:06 | ALNC |  Spire Healthcare buys Acorn Occupational Health for GBP3.3 million |
| 01/4/2025 | 07:00 | UK RNS | Spire Healthcare Group PLC Acquisition of Acorn Occupational Health Limited |
| 31/3/2025 | 12:16 | UK RNS | Spire Healthcare Group PLC Block listing Interim Review |
| 28/3/2025 | 13:09 | UK RNS | Spire Healthcare Group PLC Director/PDMR Shareholding |
| 14/3/2025 | 14:47 | UK RNS | Spire Healthcare Group PLC Director/PDMR Shareholding |
| 07/3/2025 | 14:58 | UK RNS | Spire Healthcare Group PLC Director/PDMR Shareholding |
| 06/3/2025 | 11:07 | ALNC | Spire Healthcare plunges on weak outlook amid mix shift, payroll costs |
| 06/3/2025 | 07:00 | UK RNS | Spire Healthcare Group PLC Change in Spire Healthcare's directors |
Spire Healthcare (SPI) Share Charts1 Year Spire Healthcare Chart |
|
1 Month Spire Healthcare Chart |
Intraday Spire Healthcare Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 28/3/2025 | 17:18 | Spire Health | 1,692 |
| 26/5/2021 | 07:36 | At ladt | 1 |
| 08/11/2020 | 11:22 | Unloved and Underappreciated | - |
| 24/10/2020 | 17:47 | Sunday Times view | - |
| 15/1/2017 | 13:48 | Spice Holdings PLC | 1,547 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 27/4/2025 09:20 by Spire Healthcare Daily Update Spire Healthcare Group Plc is listed in the Health & Allied Services,nec sector of the London Stock Exchange with ticker SPI. The last closing price for Spire Healthcare was 185p.Spire Healthcare currently has 402,751,824 shares in issue. The market capitalisation of Spire Healthcare is £746,701,882. Spire Healthcare has a price to earnings ratio (PE ratio) of 29.38. This morning SPI shares opened at 187p |
Posted at 23/3/2025 09:33 by masurenguy Simply Wall StreetSun 23 Mar 2025 Spire Healthcare Group: SPI Last Price: £1.74 * Consensus EPS estimates fall by 15% * The consensus outlook for fiscal year 2025 has been updated. * 2025 EPS estimate fell from UK£0.132 to UK£0.112 per share. * Revenue forecast steady at UK£1.60b. * Net Inc forecast to grow 81% next year vs 28% growth forecast for Healthcare industry in the UK. * Consensus price target down from UK£3.01 to UK£2.91. * Share price was steady at UK£1.74 over the past week. |
Posted at 15/3/2025 11:02 by quick thinker I saw that, igoe. Those videos are interesting to get some alternative views from various fund managers. I'd like to hear Christopher Mills take on it again. Spire was his favourite share for 2025 with his expectations, if I recall, being that earnings would grow substantially and debt would reduce significantly over the next couple of years. He also noted the property valuation point that Paul Hill pointed out and that there may be external interest from India to take over the business. I haven't studied the results in details but I'd be interested to dig into the debt and earnings figures to see if Christopher's view on these appear to stack up. |
Posted at 14/3/2025 17:34 by igoe104 I see paul Hill from vox markets has taken up a position in SPI, he mentioned the assets are worth a hell of alot more than the current shareprice... |
Posted at 10/3/2025 10:48 by tsmith2 JPMorgan cuts Spire Healthcare price target to 309 (321) pence - 'overweight'very modest TP reduction post update. market reaction on other hand has been brutal. |
Posted at 07/3/2025 12:52 by masurenguy Spire Healthcare’s profit to be hit by £30m costs increaseShares in private healthcare provider fall sharply as looming national insurance rise and higher energy prices take toll Rising employment and energy costs as well as a shift from self-pay to private insurance is set to hit profits at Spire Healthcare by about £30m this year, triggering a sell-off in its shares. Alongside mixed full-year results on Thursday, the FTSE 250 private healthcare company forecast adjusted profits of between £270m and £285m this year, below the City’s forecasts. Spire said this was because of a combination of April’s rise in employers’ national insurance contributions, the national minimum wage, “payor mix changes” and increased energy costs. The FTSE 250 company said that it expected to offset about £10m of these costs this year, including by accelerating cost savings and self-pay price changes. An efficiency programme, announced two years ago, including digitising administration, is “delivering ahead of plan” and will be sped-up. Spire therefore expects savings of at least £30m this year, about £10m above its initial plans. It has also expanded its 2024 to 2026 cumulative savings target to £80m, from £60m. But with its profit outlook for this year below the consensus forecast of analysts, shares in Spire were down 16%, or 36p, to close at 188½p on the London Stock Exchange. Despite today’s share declines, the stock is up about 70% over the past five years, although it remains below the 250p takeover offer from Ramsay Health Care, an Australian competitor, in 2021 which, unusually, was voted down by shareholders. Complete article: |
Posted at 07/3/2025 12:45 by ricky46 £1.4 billion of freehold property, this is more like a property fund, there spending £100 million a year on capex too, basically at this share price the whole business is valued at zero..... that's just a crazy valuation |
Posted at 06/3/2025 13:44 by ricky46 The share price is covered by the land and property alone, so your basically getting the business for free, that's what it looks like in the accounts and that's why its touted as a bid target, the NI increases were known costs before today, so surely today is just a massive over reaction, if there's potential bidders out there now seems like a good time to pounce! |
Posted at 06/3/2025 08:27 by carcosa The negatives:National Insurance (NI) & Minimum Wage (NMW) are expected to add £18m–£20m annually to costs, with an FY25 in-year impact of £13m–£15m. Though £10m of savings are planned, some cost pressures will still impact margins. The energy hedge expired in Q4 FY24, leading to higher energy expenses in FY25. Long-term solar panel installations may reduce costs, but short-term expenses will rise. Inflation-driven wage demands may outpace Spire’s ability to mitigate through efficiency savings. Increased competition for healthcare professionals could push up hiring & retention costs. NHS revenue grew 8.8% YoY, making up ~30% of total revenue. Private Medical Insurance (PMI) and Self-Pay (SP) are higher-margin segments, but more patients are switching from Self-Pay to PMI, potentially lowering margins The government’s approach to NHS funding could impact Spire’s future revenues. PMI insurers are growing market share, meaning negotiating power may shift in their favour, putting downward pressure on pricing. |
Posted at 06/3/2025 07:13 by masurenguy Spire Healthcare reports results for the year ended 31 December 2024Good financial results, strong patient satisfaction and all core metrics in line with guidance Delivered guidance, mitigating mix and cost (Unless otherwise stated, y/y growth metrics and margin expansion metrics are presented on a comparable basis1) · Revenue growth of 6.2% y/y; comprised of 5.5% y/y in Hospitals and 15.0% y/y from Primary Care services. · Payor mix evolving with stronger performance in NHS revenue, up 8.8% y/y and Private patient revenue (PMI + Self-Pay) up 4.3% y/y. · Group adj. EBITDA grew 9.0% to £260.0m. Reflecting price, acuity and cost saving benefits which provided mitigation to H2 impacts from payor mix changes and energy hedge roll off. · Group adj. EBITDA margin of 17.2%. Within this, we saw good expansion in Hospitals margin, up 30 bps y/y to 18.0% and very strong expansion in Primary Care margin up 340 bps to 8.5%. · Operating profit up 9.0% y/y on a stated basis to £137.5m, including adjusting items of £(11.9)m largely related to the transformation programme and previously disclosed remediation. · ROCE(6) increased to 8.2% (FY23: 7.5%). · Recommended final dividend of 2.3 pence per ordinary share (FY23: 2.1 pence per ordinary share). Strong strategic delivery of growth and efficiency · Cost savings accelerated: delivering >£20m in FY24 through procurement standardisation, automating booking procedures, Patient Support Centres and implementing staffing models to reduce agency use. · Vita outperforming management expectations with revenue of £107m and EBITDA £11m. · Three new Primary Care clinics opened. Meeting more patient needs and driving referrals to nearby Hospitals. · Responded to NHS demand. Increasing eRS slots and driving 20% y/y volume growth in Q4, with high Orthopaedic mix of over 60%. · Record levels of clinical permanent employment, with turnover at an all-time low of 11.5%. · Leading on quality. Average length of stay reduced for hip and knee procedures, Patient Safety Incident Response Framework implemented and Patient Survey showed 97% rated their experience as good / very good (up 1% from prior year). Outlook and current trading We are confident in delivering mid-single digit y/y percentage Group revenue growth in FY25. This will be driven by the combination of structural market expansion, good growth prospects in Hospitals and the growing demand for our Primary Care services. We continue to see evolution in the underlying mix by payor group. We anticipate strong overall demand for services, with growth in Private patients and a continued strategic partnership with the NHS. The growth in Private patients will be driven by Private Medical Insurers (PMIs), where they are reporting strong increases in policies written, which in turn will result in more activity; and working age patients increasingly being covered. The latter means we anticipate continued Self Pay (SP) switching to PMI, where our drivers for growth are focused on average revenue per case (ARPC) and mix management. As a reminder, share price procedures are our highest margin activities, followed by PMI, and NHS funded admissions. Cost savings are already delivering ahead of plan and we intend to accelerate this further. With new savings of at least £30m in FY25, which are c£10m above our original plans. At the same time we are increasing our FY24-26 cumulative savings target to £80m (was previously £60m). We expect a £(30)m EBITDA impact in FY25 as a result of National Insurance (NI) and National Minimum Wage (NMW), payor mix changes and the roll off of our energy hedge. We expect NI and NMW to add £18-20 million to operating costs on an annualised basis before mitigation, making the FY25 in-year impact c£13-15m. In FY25 we believe we can offset c£10m of NI, NMW, payor mix and energy costs combined through accelerated cost savings, driving high margin acuity mix and self-pay pricing changes. Bringing this together, we are guiding to FY25 adjusted EBITDA for the Group to be in the range of £270m to £285m. We remain committed to our medium-term financial targets. We continue to forecast ongoing revenue growth of greater than 5% for the Hospitals business. Vita is delivering ahead of plan and newly opened Spire Clinics are sending downstream revenue to nearby Hospitals. Our ambition is for Primary Care to become a >£40m EBITDA business in the medium term, delivered through significant contract wins in Mental Health/Occupational Therapy, more new Clinic openings and small M&A. Combining this together with accelerated savings, we expect to be able to neutralise NI/NMW and payor mix changes fully by 2027, enabling delivery of our medium-term ROCE and Hospital margin targets. Spire Healthcare has traded in-line with our expectations since the year end. Justin Ash, CEO of Spire Healthcare, said: "This is a good set of results, delivering all core guidance measures in a changing market. We saw revenue growth of 6.2% year-on-year and adjusted profit before tax growing 29.4%. Market fundamentals remain strong, with private medical insurance coverage growing significantly and a strong partnership with the NHS. Our strategy is delivering. We broadened our range of services to meet more healthcare needs in our hospitals, our clinics, in the community and at home; welcomed more NHS patients and invested significantly in our Hospital staff. We are playing a pivotal role in helping employees stay in work or return to work; all whilst maintaining and improving our quality of care and levels of patient safety, which remain our number one priorities. I thank all our colleagues and consultant partners for their expertise and commitment. We are excited about the future. We remain confident in the combination of structural market growth, supplemented by the potential of new Primary Care services to complement our hospitals, and a continued strategic partnership with the NHS helping to deliver waiting list reductions. In the year ahead, we will see pressure on costs as a result of National Insurance and Minimum Wage changes. However, we already have a successful efficiencies programme in place and intend to drive self-help measures even faster, partly offsetting the impact to operating costs. I am excited about our prospects for 2025 and we look forward to contributing in even greater measure to the nation's health." |
Posted at 11/5/2023 08:43 by bonzo1975 Spire Healthcare Group PLC AGM StatementSource: UK Regulatory (RNS & others)TIDMSPIRNS Number : 0236ZSpire Healthcare Group PLC11 May 2023Spire Healthcare Group plc('Spire Healthcare', 'the Group' or 'the Company')AGM STATEMENT11 May 2023Ahead of its Annual General Meeting later today, Spire Healthcare Group plc (LSE: SPI), a leading independent healthcare group in the UK, provides the following update for the period 1 January 2023 to 30 April 2023.The Board is pleased with the Group's performance during the first four months of the year. Consistent with expectations stated in our FY22 results announcement, good momentum has continued from the end of last year. We reiterate our outlook for the full year, as set out in the same announcement.We expect to announce our results for the six months ending 30 June on 14 September 2023.-Ends-For further information please contact: Spire Healthcare +44 (0)20 7427 9000 Angus Prentice - Director of Investor Relations Instinctif Partners +44 (0)20 7457 2020 Damian ReeceGuy ScarboroughRegistere |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
.png){kind=logo}
